News - Generics
American drug officials warned Canada about Oxy generics
7 December 2012
Pharmacists, medical groups and provincial governments also raised concerns, but six major drug companies were allowed to start producing generic Oxy last Monday following a scientific review by Health Canada. Aboriginal leaders in northern Ontario ...
Click on the link to read the full article at Sun News Network (This link will open in a new window)FDA Approval Process for Generics Sound, Say Officials
5 December 2012
The US Food and Drug Administration's (FDA's) recent recommendation to the manufacturers of generic extended-release bupropion (Budeprion XL 300 mg, Impax Laboratories and Teva Pharmaceuticals) that resulted in its being voluntarily withdrawn from ...
Click on the link to read the full article at Medscape (This link will open in a new window)Generic pharmaceuticals veteran Douglas Boothe will head Perrigo Co.'s ...
5 December 2012
ALLEGAN, MI -- The chief executive officer of the U.S. operations of a thriving international generics manufacturer will lead Perrigo Co.'s pharmaceutical division. Perrigo has named Douglas Boothe executive vice president and general manager of ...
Click on the link to read the full article at Michigan Business Review - MLive.com (This link will open in a new window)FDA Pulls One Generic Form of Wellbutrin Off the Market
5 December 2012
In October, the U.S. Food and Drug Administration recommended that generic Wellbutrin, or bupropion, made by Impax Laboratories and distributed by Teva Pharmaceuticals, be taken off the market, and Impax and Teva have agreed to stop shipping the drug ...
Click on the link to read the full article at U.S. News & World Report (This link will open in a new window)Strides Arcolab, Eli Lilly to expand cancer drug delivery
5 December 2012
Building on our recent investment in a Lilly-branded generics platform in China earlier this year, this agreement will help Lilly expand its portfolio and deliver high-quality cancer medicines to patients across emerging markets.? Arun Kumar, Founder ...
Click on the link to read the full article at Hindu Business Line (This link will open in a new window)US on Alert for Canadian Drugs
5 December 2012
An FDA spokeswoman said she couldn't comment on the agency's decision-making process about the generic drugs because of a pending lawsuit by Endo seeking to block approval of the generics. But she said the agency "understands how important it is to ...
Click on the link to read the full article at Wall Street Journal (This link will open in a new window)Generic drug makers see drought ahead
4 December 2012
Next year, the value of drugs scheduled to lose their patents and be sold as generics is expected to decline by more than half, to about $17 billion, according to an analysis by Credit Agricole Securities. ?The patent cliff is over,? said Kim Vukhac ...
Click on the link to read the full article at Livemint (This link will open in a new window)Generics makers use familiar tactics to fight their own patent cliffs
4 December 2012
And now that Big Pharma's makeover is well under way, it's Big Generics' turn. Yes, the expiring patents on Big Pharma's biggest drugs have been a windfall for copycat drugmakers. One top-selling product after another has gone generic, giving companies ...
Click on the link to read the full article at FiercePharma (This link will open in a new window)Should FDA usher old-style opioid generics onto the market?
4 December 2012
On the other, generic drugmakers that want to introduce copies of big-selling, high-powered painkillers. In the middle, the FDA, which has to decide whether to allow those cheap copies onto the market. The powerful drugs in question include the ...
Click on the link to read the full article at FiercePharma (This link will open in a new window)Patent expiries trigger pain drugs battle
4 December 2012
Looming patent expiries on powerful pain medicines have triggered a battle for control of the $9bn prescription market between pharmaceutical groups and competitors making generic versions of the drugs. Generic drug companies are lobbying the US Food ...
Click on the link to read the full article at Financial Times (This link will open in a new window)
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
